- Home
- MDCX vs ANTX Comparison
MDCX vs ANTX Comparison
Compare MDCX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | ANTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 31.2M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MDCX | ANTX |
|---|---|---|
| Price | $0.95 | $1.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.50 | $2.00 |
| AVG Volume (30 Days) | ★ 375.5K | 72.6K |
| Earning Date | 03-27-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.00 |
| 52 Week High | $8.94 | $1.55 |
Technical Indicators
Market Signals| Indicator | MDCX | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 21.00 | 45.41 |
| Support Level | $1.09 | $1.05 |
| Resistance Level | $1.29 | $1.14 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.17 | 30.28 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.